EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC

Millicent Dockerill, Richard J Payne iD, Nicolas Winssinger iD

Angewandte Chemie International Edition · 14.09.2026 · 65 (38)

DOI: 10.1002/anie.5778436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 15.07.2026. Verfasst von Millicent Dockerill und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry, Faculty of Sciences, University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Thrombin, Combinatorial Chemistry Techniques, Peptide Nucleic Acids, Drug Discovery. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dynamic combinatorial chemistry (DCC) offers a powerful yet underutilized strategy for ligand discovery, largely limited by heterogeneous kinetic constraints in exchange reactions and analytical challenges. Here we report a peptide nucleic acid (PNA)‐templated trivalent DCC platform that enables rapid, target‐guided exploration of 125 000 assemblies to identify ultrahigh‐affinity and reversible thrombin inhibitors. Short hybridization handles allow unbiased equilibration of a three‐fragment library, and size‐exclusion filtration combined with matrix‐assisted laser desorption/ionization mass spectrometry (MALDI‐MS) provides a complete selection–readout cycle in under 1 h. From this library, thrombin amplifies synergistic fragment combinations engaging the active site and both exosites, yielding a trivalent inhibitor with apparent sub‐picomolar affinity ( K D ≈ 84 fM) and near‐stoichiometric inhibition. Despite its extreme potency, inhibition remains fully reversible: addition of a single‐stranded toehold antidote rapidly disassembles the complex and restores activity in buffer and in plasma. These results establish hybridization‐guided DCC as a fast, scalable route to programmable multivalent therapeutics with on‐demand reversibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombinCombinatorial Chemistry TechniquesPeptide Nucleic AcidsDrug DiscoveryAntithrombinsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationHumans

Stichwörter der Autor:innen

active sitechemistrycombinatorial chemistryligandmass spectrometrymass spectrometry imagingnucleic acidpeptide nucleic acidthrombin

Substanzen

ThrombinPeptide Nucleic AcidsAntithrombins

Autor:innen und Institutionen

  • Department of Organic Chemistry, Faculty of Sciences, University of Geneva, Geneva, Switzerland.
  • School of Chemistry, The University of Sydney, Sydney, New South Wales, Australia.
  • Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Richard J Payne, Nicolas Winssinger

Förderung

  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Dockerill, M., Payne, R. J., & Winssinger, N. (2026). Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC. Angewandte Chemie International Edition, 65(38). https://doi.org/10.1002/anie.5778436

Vancouver

Dockerill M, Payne RJ, Winssinger N. Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC. Angewandte Chemie International Edition. 2026;65(38). doi:10.1002/anie.5778436

BibTeX
@article{Dockerill2026,
  author = {Dockerill, Millicent and Payne, Richard J and Winssinger, Nicolas},
  title = {Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC},
  journal = {Angewandte Chemie International Edition},
  year = {2026},
  volume = {65},
  number = {38},
  doi = {10.1002/anie.5778436}
}
Kostenlos starten →